Modulight and Bausch + Lomb team for ocular laser
Finnish medical laser technology developer Modulight has entered into an exclusive agreement with global eye health company Bausch + Lomb to develop a new photodynamic laser.
The two companies will collaborate and develop a new laser to be used specifically with Bausch + Lomb’s VISUDYNE photodynamic therapy (PDT).
The method uses the injectable photosensitising drug VISUDYNE, which is activated through the use of a photodynamic laser, to treat choroidal neovascularisation in the eye. It helps to prevent further disease progression and helps patients to maintain their vision by destroying abnormal choroidal blood vessels.
“Bausch + Lomb has identified a significant need in the ophthalmic industry and we believe this is a great opportunity to develop a state-of-the-art photodynamic laser to allow customers to continue to provide this type of therapy for their patients. We look forward to a strong promising collaboration.”